1. Home
  2. INFU vs IPHA Comparison

INFU vs IPHA Comparison

Compare INFU & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InfuSystems Holdings Inc.

INFU

InfuSystems Holdings Inc.

HOLD

Current Price

$8.92

Market Cap

182.2M

Sector

Health Care

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.78

Market Cap

174.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INFU
IPHA
Founded
2005
1999
Country
United States
France
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
182.2M
174.2M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
INFU
IPHA
Price
$8.92
$1.78
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$14.50
$5.00
AVG Volume (30 Days)
110.9K
27.0K
Earning Date
11-04-2025
09-17-2025
Dividend Yield
N/A
N/A
EPS Growth
271.43
N/A
EPS
0.26
N/A
Revenue
$141,054,000.00
$14,839,695.00
Revenue This Year
$8.82
$22.29
Revenue Next Year
$2.90
$43.90
P/E Ratio
$34.58
N/A
Revenue Growth
6.23
N/A
52 Week Low
$4.61
$1.60
52 Week High
$11.04
$2.63

Technical Indicators

Market Signals
Indicator
INFU
IPHA
Relative Strength Index (RSI) 40.80 47.30
Support Level $8.71 $1.63
Resistance Level $9.03 $1.83
Average True Range (ATR) 0.29 0.10
MACD -0.01 -0.00
Stochastic Oscillator 20.52 51.61

Price Performance

Historical Comparison
INFU
IPHA

About INFU InfuSystems Holdings Inc.

InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. INFU services are provided under a two-reportable segment. The first is Patient Services, providing the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex durable medical equipment and services. The Patient segment is comprised of Oncology, Pain Management and Wound Therapy businesses. The second, Device Solutions, supports the Patient Services platform and leverages service orientation to win incremental business from its direct payer clients. The Device segment is comprised of direct payer rentals, pump and consumable sales, and biomedical services and repair. Majority from Patient.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Share on Social Networks: